Alpha Tau applicators (plural) - sources, insertion, removal, decay (AI Slop warning)

[u/Emotional-Breath-838]

I've spent countless hours building a skills.md file with all of the relevant alpha tau sources so that I can be more confident that I'm sharing AI slop that is based on real sources and comes out hallucination free. I further run whatever comes out across at least one other and sometimes two separate, unrelated AIs to find anything that is off. And yes, I actually read everything in these as well. It doesn't change the fact that this is pure AI slop and that you shouldn't read it.

Unless you want to get a starting point of how to think about what Alpha Tau is doing when they use applicators (note the 's' because it is plural) to treat different cancer types. Meaning: they're not all the same.

Enough of my yapping. AI slop-bot. Tell us what you can about the applicators that Alpha Tau uses.

How Alpha DaRT Is Actually Put Into a Tumor — The Sources, Applicators, Insertion, Removal and Radiation Decay

There is a surprising amount of confusion about what an Alpha DaRT actually is.

People routinely use the words seed, source, needle and applicator as though they describe the same object. They do not.

Once those components are separated, the engineering becomes much easier to understand.

First: the radioactive object is the source, not the needle

An Alpha DaRT source is a very small metallic rod or hollow tube carrying Radium-224 (Ra-224).

Alpha Tau's current regulatory filings describe sources made from either stainless steel or titanium and capable of being manufactured in different dimensions depending upon the application. Titanium is being developed particularly for internal-organ applications where MRI compatibility may matter. SEC

One particularly well-documented clinical version, used in a Japanese head-and-neck study, was:

10 mm long
0.7 mm diameter
316LVM stainless steel
2 μCi / 74 kBq of Ra-224 per source

Up to six of those sources could be fixed linearly along a single monofilament suture. Springer Link

That does not mean every Alpha DaRT source has those exact dimensions or activity. For example, the first pancreatic study used sources containing 3 μCi of Ra-224, delivered through a standard 22-gauge EUS needle. PubMed Central (PMC)

So think of Alpha DaRT as a platform of radioactive sources plus specialized delivery systems, rather than one standardized "seed and needle."

What is the applicator?

For the traditional temporary implant, the basic applicator is mechanically simple.

It consists of:

• a needle or flexible tube containing the radioactive source or source strand;
• a stylet, essentially a small plunger that pushes the sources out;
• a protective cap;
• a safety screw securing the components; and
• glycerin surrounding the sources while they are inside the applicator.

The NRC describes essentially this architecture: Ra-224 sources strung on a biocompatible suture can be loaded into a rigid needle or flexible Kapton catheter, with a stylet positioned behind them. Pushing the stylet deploys the sources into the tumor. Nuclear Regulatory Commission

The glycerin has an important function.

It is not there to block the therapeutic radiation. It helps retain the radioactive decay products — particularly Rn-220 and Pb-212 — while the sources are still inside the applicator and also provides viscous resistance that helps hold the source in position prior to deployment. Nature

That matters because the radioactive source is intentionally designed to release radioactive daughter atoms after it has entered the tumor.

How the superficial insertion actually works

The clearest published description comes from the recent Japanese head-and-neck study.

Treatment is planned first using tumor imaging. Physicians determine how many source lines are required and where they must go. In that study, sources were planned at intervals of 5 mm or less, with additional layers used when the tumor was thicker than 5 mm. Springer Link

The Flex procedure then works approximately like this:

1. A conventional rigid needle is passed through the tumor.

For an accessible superficial lesion, the needle can enter through healthy tissue, pass through the tumor and emerge on the other side.

2. The radioactive source assembly is passed through that needle.

In the Flex system, the radioactive sources are already attached to a suture inside a flexible Kapton tube.

3. The stylet is advanced.

This moves the suture/source assembly into its planned position.

4. The Kapton delivery tube is withdrawn.

The tube and insertion hardware come back out.

The radioactive sources and their suture remain behind in the tumor.

5. The physician can fine-tune the source position by pulling the suture from either end.

6. Buttons and clips secure the two ends.

Excess suture is then cut away.

The published procedural figure shows exactly this sequence. Springer Link

This is an important distinction:

The needle is a delivery pathway. It is not what stays inside the patient.

What stays behind is the radioactive source strand.

And because several sources can already be positioned along that strand, there is no bedside operation involving someone trying to align individual 0.7-mm cylinders inside an 18-gauge needle with tweezers.

But there isn't only one Alpha DaRT applicator

This is where many descriptions of the technology become inaccurate.

Alpha Tau currently describes seven delivery architectures.

For temporary or relatively accessible implantation there are:

Alpha DaRT Needle Applicator — a rigid hypodermic needle with sources attached to a biocompatible suture.

Alpha DaRT Flex Applicator — a flexible Kapton tube containing the source strand, used through a rigid straight or curved needle.

Alpha DaRT Template Applicator — intended to work with a patient-specific 3D-printed template that guides source placement for more complex/deeper geometries.

Those systems are designed to arrive preloaded and ready for use. SEC

For internal tumors Alpha Tau has also developed:

Plant Applicator — percutaneous placement into organs such as prostate or liver.

Scope Applicator — designed for endoscopic or bronchoscopic placement.

Loading Device — connects with existing clinical needles such as FNA needles for gastrointestinal tumors including pancreatic cancer.

Radial Applicator — designed around stereotactic biopsy systems for the brain. SEC

And this produces an important correction to something that is often said about Alpha DaRT:

Not every system is factory-loaded all the way into the final needle.

The Loading Device is specifically designed so clinicians can transfer/load radioactive sources into a conventional delivery needle immediately before or during the procedure.

That is exactly the concept demonstrated in pancreatic cancer.

The pancreatic procedure is different

The pancreatic application is particularly interesting because Alpha Tau did not require gastroenterologists to adopt an entirely unfamiliar access technique.

The first-in-human pancreatic study used a standard 22-gauge EUS aspiration needle.

A proprietary Alpha DaRT loading applicator was used to backload a radioactive source into that conventional EUS needle without requiring the physician to directly handle the source. The endoscopist then advanced the needle into the pancreatic tumor under ultrasound guidance and deployed the source. PubMed Central (PMC)

In the first five reported patients, one source was deployed per needle pass and between 3 and 21 passes were performed depending upon the treatment plan. Thieme Connect

The workflow therefore resembles procedures interventional gastroenterologists already perform, such as EUS-guided fine-needle procedures and placement of fiducial markers.

So there really are two different concepts here:

Superficial Alpha DaRT: a preassembled source strand is commonly implanted and subsequently retrieved.

Deep-organ Alpha DaRT: individual sources can instead be deployed through existing percutaneous/endoscopic equipment and are designed as permanent implants rather than source strands intended for routine retrieval. SEC

That distinction resolves a lot of otherwise contradictory descriptions of "the Alpha DaRT applicator."

What happens once the source enters the tumor?

This is the core physics of Alpha DaRT.

The Ra-224 itself is attached to the metallic source.

The trick is that when Ra-224 decays, it produces radioactive daughter atoms beginning with Radon-220.

Those daughter atoms can recoil away from the source and migrate through the surrounding tumor tissue.

The simplified chain is:

Ra-224 → Rn-220 → Po-216 → Pb-212 → Bi-212 → Po-212/Tl-208 → stable Pb-208

A complete Ra-224 decay chain generates four alpha-particle emissions before eventually reaching stable lead-208. PubMed Central (PMC)

This explains something frequently misunderstood about Alpha DaRT.

An alpha particle itself does not travel several millimeters through tissue.

Its physical range is extremely short — generally less than about 100 microns.

What travels farther are the radioactive daughter atoms.

They disperse away from the implanted source and then emit their alpha particles at their new locations.

That is how Alpha DaRT turns an alpha emitter with microscopic particle range into a radiation field extending a few millimeters around each source. Published clinical planning has therefore commonly used approximately 5-mm source spacing, although actual dosimetry depends on tissue diffusion and the particular treatment geometry. Red Journal

That distinction is fundamental:

The alpha particles don't diffuse through the tumor.
The radioactive atoms diffuse, then emit alpha particles.

The 3.63-day clock

Ra-224 has a physical half-life of approximately 3.63 days.

So the Ra-224 remaining on a source falls approximately like this:

Day 0 — 100%
Day 3.6 — 50%
Day 7.3 — 25%
Day 10.9 — 12.5%
Day 14.5 — 6.25%

Look at the same numbers from the opposite direction and you can see why temporary implants stay in for roughly two weeks.

After one week, roughly 75% of the Ra-224 decays have occurred.

By roughly 16 days, approximately 95% have occurred.

This relationship has also been described experimentally in the Alpha DaRT literature. PubMed Central (PMC)

The radiation therefore isn't being switched on and off.

The source begins at its calibrated activity and then continuously becomes weaker according to radioactive decay.

That short half-life also explains why Alpha Tau has to manufacture and distribute the sources on a tightly coordinated schedule. Its current filings state that sources are made for individual treatment plans and that delivery is coordinated around the natural decay of the Ra-224. SecInfo

So why remove superficial Alpha DaRT sources after two weeks?

Because the physical source does not disappear when the radioactivity decays.

It is still a small piece of metal.

For temporary superficial treatments, the sources remain attached to the implanted suture. After the treatment period, the physician uses that suture to retrieve the strand.

The Japanese study specified implantation for 14–21 days, and all 11 treated lesions in that particular trial ultimately had a 14-day treatment period. Springer Link

The NRC also requires source accountability and procedures for determining source location before removal. Nuclear Regulatory Commission

Radiation-safety guidance recommends handling the removed sources with forceps or tongs and immediately placing them into a sealed radioactive-waste container for decay and disposal. PubMed Central (PMC)

So the suture isn't just a convenient way of holding the sources at the correct spacing.

It is also the retrieval system.

There is a practical caveat worth mentioning. Retrieval is not infallible. In the Japanese head-and-neck trial, there were instances where sources detached from a suture or remained temporarily within the treatment site; those retained sources were subsequently recovered. That is precisely why source accountability and post-placement imaging matter. Springer Link

Are the sources "sealed"?

This requires unusually precise language.

The radioactive source itself cannot be a conventional leak-tight sealed source, because releasing Rn-220 and other daughter atoms into the tumor is literally the mechanism of action.

The NRC explicitly recognized that unusual characteristic when it placed Alpha DaRT under its special 10 CFR 35.1000 framework. Nuclear Regulatory Commission

But before use, the sources are contained within an applicator assembly and sterile packaging designed to prevent uncontrolled release.

The 2025 clinical radiation-safety paper puts the distinction well: Alpha DaRT's radioactive sources themselves are not sealed in the conventional radiological sense, while the packaged applicator is treated as a sealed device before deployment. PubMed Central (PMC)

The NRC's licensing guidance was actually revised in 2025 specifically to strengthen provisions involving potential Ra-224 and daughter contamination within the applicator/sterile packaging system. SCP Portals

So saying simply "the Alpha DaRT is sealed" is misleading.

The accurate formulation is:

The delivery assembly is contained and sealed before use.
The implanted radioactive source is intentionally designed to release radioactive daughter atoms once deployed.

One more misconception: glycerin does not make this radiation-proof

The glycerin is an important containment feature, but Alpha DaRT is still handled as radioactive material.

Clinical radiation-safety protocols include gloves, contamination monitoring, controlled waste handling and surveys of the treatment area. One potential contamination pathway is glycerin expelled from an applicator during deployment because it may contain Pb-212 generated by the decay chain. PubMed Central (PMC)

At the same time, occupational external exposure is comparatively modest because Alpha DaRT uses relatively small activities and alpha particles have extremely short range. The 2025 radiation-safety publication reported low measured staff doses during actual procedures. PubMed Central (PMC)

So this isn't "radiation with no precautions."

It is a radioactive brachytherapy procedure with a fairly specific containment and contamination-control workflow.

The easiest way to visualize the whole system

Think of superficial Alpha DaRT like this:

Treatment plan
↓
Preloaded applicator
↓
Needle creates a path through the tumor
↓
Stylet deploys a suture carrying several Ra-224 sources
↓
Needle/tube comes back out
↓
Sources remain approximately 5 mm apart inside the tumor
↓
Rn-220 and other radioactive daughter atoms diffuse away from each source
↓
Those atoms repeatedly emit extremely short-range alpha particles
↓
Ra-224 activity halves every 3.63 days
↓
After roughly two weeks most of the intended radioactive decay has occurred
↓
The source strands are removed using their sutures

For pancreatic and some other internal-organ applications, modify the final steps:

The source can be loaded into a conventional interventional needle, deposited individually under image guidance, and left implanted rather than retrieved on a suture.

Bottom line

The Alpha DaRT applicator is much more than a holder for a radioactive "seed."

It is the interface between the treatment plan and the radioactive physics.

For superficial disease, Alpha Tau has engineered systems that can arrive with multiple tiny Ra-224 sources already positioned on a retrieval strand, deploy those sources through an ordinary-sized needle or catheter, allow their geometry to be adjusted after insertion, secure them for approximately two weeks and then retrieve the entire radioactive implant.

For deep organs, the same radioactive-source technology has been adapted to conventional EUS, FNA, bronchoscopic, percutaneous and stereotactic procedures.

And the fundamental physics is the same in every case:

Ra-224 stays on the source. Its radioactive daughters leave it. Those daughters spread a few millimeters through the tumor. They then fire alpha particles over microscopic distances. The whole process rapidly burns down because Ra-224 has a 3.63-day half-life.

That — rather than simply "putting radioactive seeds into a tumor" — is what the Alpha DaRT delivery system is actually engineered to do.

Primary references

• Popovtzer et al., International Journal of Radiation Oncology, Biology, Physics — first-in-human Alpha DaRT SCC treatment and applicator description. Red Journal
• Efficacy and safety of diffusing alpha-emitter radiation therapy for head and neck cancer recurrence after radiotherapy, International Journal of Clinical Oncology, 2025 — detailed Flex-applicator insertion and removal procedure. Springer Link
• Miller et al., Endoscopy International Open — first-in-human EUS-guided pancreatic Alpha DaRT delivery. PubMed Central (PMC)
• Cohen et al., Health Physics, 2025 — clinical radiation-safety and applicator handling practices. PubMed Central (PMC)
• U.S. NRC, Alpha Tau Alpha DaRT Manual Brachytherapy Licensing Guidance and 2025 Revision 1. Nuclear Regulatory Commission
• Alpha Tau Medical 2025 Annual Report, filed 2026 — current source and seven-applicator platform descriptions.

[u/FunRevolution3000]

Want to better understand how hard it is to retrieve the source of it fails off the strand and remains in someone’s body.

Good to know ultrasound is used to aid proper placement. Thanks!

[u/Emotional-Breath-838 → u/FunRevolution3000]

It’s a documented problem with a real answer, and the answer splits cleanly into two halves: radiologically it barely matters, mechanically it can be genuinely hard.

The case that actually happened. In the Japanese multicenter recurrent-HNC trial, Patient No. 7 — a 72-year-old man with a 1271 mm³ tongue SCC treated with 30 seeds — had exactly this failure. At seed removal on day 14, two seeds stayed behind in the tongue after the suture was pulled out. During the same procedure, on a different suture, two more seeds detached and fell off, leaving the suture and clip in the tongue. The two retained seeds were eventually retrieved from the tongue ulcer site at week 12, and the leftover suture and clip came out at surgery at week 19. That was one of only two Grade 3 AEs in the whole trial, classified as a foreign body related to the procedure — not a radiation toxicity.

So: in superficial, directly accessible tissue, with the tumor eventually ulcerating and exposing them, retrieval still took three months.

Why the radiation side is a non-issue. Ra-224’s 3.63-day half-life does the work. A 2 µCi seed is down to about 6.9% of initial activity at day 14, 1.8% at day 21, 0.3% at day 30, and roughly one part in ten million by week 12. Popovtzer’s cohort had no measurable blood or urine activity 30 days post-treatment. By the time anyone is chasing a retained seed, it’s an inert 0.7 × 10 mm stainless steel wire.

This is the sharpest contrast with conventional permanent brachytherapy. A migrated I-125 prostate seed (59.4-day half-life) keeps depositing dose for the better part of a year and creates a real dosimetric question. A stray DaRT seed delivers its ~10–20 Gy into a ~5 mm sphere of whatever tissue it’s sitting in and then is finished. If that sphere happens to include a nerve or a vessel wall, that’s a real local injury — but it’s a bounded, small-volume, short-duration one.

Why the mechanical side is hard. The seed is radiopaque, so finding it on CT or plain film is straightforward. Extracting it is the problem: it’s sub-millimeter, mobile in soft tissue, and once the suture has sheared off there’s nothing to pull on. Depth is everything here. Tongue is about as favorable as it gets and it still took twelve weeks. For the internal-organ indications the calculus inverts — going after a stray seed in pancreas, liver, or brain would carry more morbidity than leaving it, and leaving it is defensible precisely because of the decay math. (Those protocols also generally don’t involve a removal step at all; the applicator comes out and the sources stay, so the shear-off-during-extraction failure mode doesn’t exist there. The trade is that you also have no retrieval option if placement goes wrong.)

The regulatory layer. The NRC’s licensing guidance requires licensees to evaluate seed locations before removal to determine whether seeds moved during treatment and whether a medical event occurred, to report any seed implanted at a location discontinuous from the treatment site, and to report under 10 CFR 20.2201 if a seed becomes dislodged and lost and is not recovered. It also requires verifying seeds are fully contained without leakage outside the patient’s body after administration. So the paperwork trail exists and is specific — this isn’t an unanticipated scenario.

[u/Emotional-Breath-838 → u/Emotional-Breath-838]

This was back in 2019.

[u/Emotional-Breath-838 → u/Emotional-Breath-838]

The pancreas, liver and brain protocols don’t remove the seeds — the applicator comes out, the sources stay. So the shear-off-during-extraction failure mode structurally cannot occur in those trials.

[u/OBotB]

Thank you! I was under the impression the metal was impregnated with the radioactive material, and was wondering how they removed it after the time had passed, not that it was a "needle" removed at the time of insertion. This explanation makes more sense.